Results: The limits of quantification (CV <20%) determined by adding the proteins to uPAR-depleted plasma were <3 pmol/L in all three assays. The interassay CVs were <11%, and recoveries were between 93% and 105%. Cross-reactivities of purified proteins in the three TR-FIAs were no more than 4%. Studies on chymotrypsin cleavage of uPAR and size-exclusion chromatography of plasma with and without added protein further supported the specificity of the assays.
sults). uPAR may be shed from cells either by phospholipase hydrolysis of the lipid anchor or by proteolytic cleavage (10, 11 ) . A soluble form of uPAR(I-III) has been identified in plasma from healthy individuals and in patients with paroxysmal nocturnal hemoglubinuria (12 ) . Interestingly, the uPAR concentration is increased in blood from patients with non-small-cell lung cancer (13 ) , colon cancer (14 ) , and breast cancer (15 ) . Furthermore, a cleaved soluble form, uPAR(II-III), has been identified in cystic fluid from ovarian cancer patients (16 ) , and immunoprecipitation and Western blotting have revealed that urine samples from patients with acute myeloid leukemia contain uPAR(I) and uPAR(II-III) (17 ) .
It has previously been reported that increased concentrations of uPAR in resected tumor tissue are correlated with poor prognosis for patients with squamous cell lung cancer (18 ) , colon cancer (19 ) , and breast cancer (20 ) . Furthermore, the amount of uPAR in preoperatively collected plasma from patients with colorectal cancer was significantly correlated to patient prognosis (21 ) . Similar results have been obtained recently with serum from patients with primary breast cancer (15 ) .
These results have demonstrated the strong prognostic potential of quantitative uPAR immunoassays and encourage additional studies of assays that not only measure a combination of various forms of uPAR but also differentiate among full-length and cleaved uPAR forms by use of selective monoclonal antibodies (Mabs). The amounts of uPAR fragments in tissues and circulation may reflect the activity of the plasminogen activation system and thus have a stronger prognostic significance than the traditional measurements of only the total uPAR content.
Cancers of the breast, prostate, colon, and lung all have high incidences, and there is a strong need for new methods that enable early detection and stratification of patients at high vs low risk of recurrence to assist in selection of patients for adjuvant therapy. To enable studies of the diagnostic and prognostic potential of the individual uPAR forms, we have designed sensitive and specific time-resolved fluorescence immunoassays (TR-FIAs) that reliably identify and accurately quantify the individual uPAR forms in blood plasma.
Materials and Methods biological samples
Pools of donor EDTA and citrate plasma were obtained as described previously (13, 14 ) . Archival serum and EDTAplasma samples were from a collection described previously (22 ) . Blood from six healthy volunteers at the Department of Biotechnology, University of Turku, Finland, was collected by venipuncture in tubes containing either no additional agents or EDTA. These samples were processed within 1 h after venipuncture and frozen immediately. EDTA plasma from a patient with prostate cancer was from Department of Clinical Chemistry, University Hospital Malmö , Sweden (Prof. Hans Lilja). Urine from a patient with acute myeloid leukemia was from an earlier described study (17 ) . The procedures followed were in accordance with the Helsinki Declaration of 1975. 
reagents and instrumentation

Mabs, peptide antagonist, and recombinant proteins
The monoclonal anti-uPAR antibodies R3, R5, and R9 all react with uPAR(I) and were raised against human uPAR purified from phorbol 12-myristate 13-acetate stimulated U937 cells (23 ) ; U937 is a histiocytic lymphoma cell line. R3 is a competitive inhibitor of uPA binding (23, 24 ) , whereas R5 and R9 actively displace receptor-bound uPA (24 ) . The anti-uPAR Mab R2 reacts with an epitope located on uPAR(III) (24 ) and is from the same fusion as R3, R5, and R9 (23 ) . The fifth anti-uPAR Mab used in this study is denoted R23 and was raised against recombinant uPAR(I-III) (25 ) . R23 is a competitive inhibitor of uPA binding and reacts with uPAR(II-III) but fails to recognize isolated uPAR(II) or uPAR(III) (List et al., unpublished data) .
AE120 is a synthetic peptide antagonist of the uPAuPAR interaction (26 ) and has the amino acid sequence [D-Cha-F-s-r-Y-L-W-S] 2 -␤A-K; where "Cha" is ␤-cyclohexyl-l-alanine, "s" is d-serine, and "r" is d-arginine. The K d value of AE120 for immobilized uPAR has been determined by surface plasmon resonance to be 0.6 nmol/L (26 ) .
Recombinant uPAR(I-III), consisting of amino acids 1-277 (calculated mass, 30 741 Da), was produced in Chinese hamster ovary cells and purified by immunoaffinity chromatography as described previously (25 ) . Human uPAR(II-III), consisting of amino acids 88 -277 (calculated mass, 21 006 Da), was generated by chymotrypsin cleavage of recombinant uPAR(I-III) (27 ) and purified by size-exclusion chromatography using a Sephadex HR 75 column (28 ) . uPAR(II-III) purified from U937 cells is a mixture of two forms with either A 84 or S 90 as the NH 2 -terminal amino acid (7 ) .
Recombinant uPAR(I), consisting of amino acids 1-92 (calculated mass, 10 400 Da), was produced in a Drosophila Expression System (Invitrogen). The expression vector pMTC-uPAR(I) was constructed by generating a fragment encoding uPAR(I) by standard PCR techniques using Pfu DNA polymerase followed by cloning into the plasmid pMT/V5-His. In brief, with pCI-neo/suPAR as template (29 ) , a SpeI site was introduced in front of the noncoding 5Ј end, and a TAA stop codon followed by an EcoRI site was introduced in the 3Ј end at the position immediately after the nucleotides encoding amino acid 92 of uPAR. The native signal sequence of uPAR is retained in this construct, allowing the recombinant uPAR(I) to be produced as a secreted soluble product. Drosophila S2 cells were stably transfected with pMTC-uPAR(I) and propagated for large-scale production as described previously (30 ) . uPAR(I) was purified from the conditioned medium of S2 cells by immunoaffinity chromatography using Mab R3 followed by reversed-phase HPLC as described previously (29 ) .
The purified uPAR(I-III), uPAR(II-III), and uPAR (I) preparations used in this study were all Ͼ95% pure as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Coomassie staining of reduced and alkylated samples (data not shown). The exact protein contents of these samples were determined by amino acid analysis (25 ) .
Active site mutated pro-uPA S356A was produced by Drosophila S2 cells and purified from the medium by immunoaffinity chromatography (Gårdsvoll et al., unpublished results). The protein was converted to twochain uPA by incubation with immobilized plasmin.
coating and europium labeling of Mabs Antibodies were treated with acid before coating. In brief, one volume of antibody solution (1 g/L) was incubated with six volumes of 0.01 mol/L HCl (pH ϳ1.8) for 5 min, after which the antibody was diluted to 5 mg/L in 0.1 mol/L NaH 2 PO 4 (pH ϳ4.2). This solution was used for coating of White Maxisorp microtitration fluorostrips (NUNC) overnight at room temperature (200 L/well) in a moisturized container. Subsequently, the plates were washed twice with wash solution containing 0.5 mL/L Tween 20 and blocked with a solution containing 50 mmol/L NaH 2 PO 4 , 1 g/L diazolidinyl urea, 60 g/L sorbitol, and 1 g/L diethylenetriaminepentaacetic acidpurified bovine serum albumin (300 L/well). The following day, plates were emptied, dried for 3 h in a fume hood, and then covered with sealing tape. Coated plates could be stored for up to 4 weeks at 4°C. 
separation of uPAR forms by chromatography
Samples, including the donor EDTA-plasma pool with or without added proteins and the patient EDTA plasmas and urines described above, were analyzed by sizeexclusion chromatography using a Superdex 75 HR 10/30 column. The samples were filtered through 0.22 m filter before use. Tris-saline-azide buffer [500 mmol/L Tris-HCl (pH 7.8), 9 g/L NaCl, 5 g/L NaN 3 ] containing 1 mol/L EDTA was used for elution. The biological samples were diluted in this buffer (1:1 by volume) before loading on the column. Collected fractions were stored at Ϫ80°C.
assay designs
The designs of the individual assay are outlined in Fig. 1 .
TR-FIA 1 for quantification of uPAR. The Mab R2 was used for coating according to the procedure described. Calibrators [threefold serial dilutions of uPAR(I-III) ranging from 0.455 to 325 pmol/L] and samples were diluted in assay buffer and added to the plates in duplicates (100 L/ well), followed by incubation with shaking for 1 h at room temperature. After six washes, 100 L of Eu 3ϩ -labeled R3 (R3-Eu) was added (1 mg/L) and incubated 2 h at room temperature with shaking. After another six washes, 100 L of enhancement solution was added to each well and incubated for 5 min at room temperature with shaking; the fluorescence was then measured with a FluoStar Galaxy fluorometer with excitation set at 405 nm and emission read at 615 nm with a 400-s delay and a 400-s acquisition window. 
TR-FIA 2 for quantification of uPAR(I-III) and uPAR(II-III).
With the exception that the detecting antibody was replaced by the E 3ϩ -labeled R23, the protocol for TR-FIA 2 was identical to that outlined for TR-FIA 1. uPAR(I-III) was used as calibrator because the antibody detects uPAR(II-III) and uPAR(I-III) with the same affinity ( Table  1) .
TR-FIA 3 for quantification of uPAR(I).
Overall the protocol was the same as for the other assays except that Mab R5 was used for coating, the sample incubation time was 2 h, and recombinant uPAR(I) was used as calibrator (threefold serial dilution ranging from 1.3 to 961 pmol/L). Because none of the available antibodies could differentiate between uPAR(I-III) and uPAR(I), we made use of the high-affinity peptide antagonist, AE120. This peptide reacts only with uPAR(I-III) and is a competitive inhibitor for uPA binding (26 ) . R3 is also a competitive inhibitor of uPA binding (23, 24 ) , and we tested the possible detection of the uPAR(I-III)-AE120 complex by this Mab. As shown in Fig. 2 this peptide at 1 mol/L almost completely prevented the binding of R3-Eu to uPAR(I-III). Accordingly, AE120 (1 mol/L) was added together with the detecting antibody R3-Eu.
immunoassay validation
Sensitivity. The reproducibility of the calibration curve was determined by analyzing the variation of duplicate measurements of calibrators in assay buffer (n ϭ 12 plates). The detection limit was defined as the concentration at which the signal exceeded 3. . In brief; 813 nmol/L uPAR(I-III) was incubated at room temperature with 2.5 g/L of either trypsin or chymotrypsin. Aliquots were withdrawn after incubation for 15 min, 30 min, 1 h, 2 h, 4 h, and 3 days and stored at Ϫ80°C until analyzed by TR-FIA and Western blotting methods. The primary antibodies used in Western blotting were 5 mg/L R2 for detection of uPAR(II-III) and uPAR(I-III), and a mixture of R3 and R9 (2.5 mg/L each) for the detection of uPAR(I) and uPAR(I-III) The membranes were developed with the WesternBreeze Chemiluminescent Immunodetection System for detection of mouse primary antibodies (Invitrogen). A separate set of these samples were subjected to size-exclusion chromatography, and collected fractions were stored at Ϫ80°C before analysis by TR-FIA.
Finally, 961 pmol/L uPAR(I), 333 pmol/L uPAR(II-III), or 325 pmol/L uPAR(I-III) was added to donor EDTA plasma samples, which were then subjected to sizeexclusion chromatography. The collected fractions were stored at Ϫ80°C before analysis by TR-FIA. To evaluate the impact of uPA/uPAR complex formation on the three TR-FIAs, we preincubated equal volumes of 23 nmol/L uPAR(I-III) and 5, 10, 20, 30, or 60 nmol/L recombinant two-chain uPA S356A on ice for 1 h. Each sample was then diluted to 325 pmol/L uPAR and serially diluted threefold, as for a calibration curve, and measured in the three TR-FIAs as well as in an ELISA (33 ) .
Precision and accuracy. We determined intraassay precision by assaying 12 replicates of donor citrate plasma in the three TR-FIAs and calculating the CVs. In addition, donor citrate plasma to which 480 pmol/L uPAR(I) or 162 pmol/L uPAR(I-III) had been added were assayed, with more than 70 replicates in each assay. All samples were diluted 1:10 in assay buffer before analysis.
We determined interassay precision by analyzing donor citrate plasma (n ϭ 47) and the donor citrate plasma to which the protein had been added (n ϭ 21 for TR-FIA 1; n ϭ 20 for TR-FIA 2; and n ϭ 23 for TR-FIA 3). All samples were diluted 1:10 in assay buffer before analysis.
We determined assay accuracy by measuring the recoveries of calibrators {0. Robustness. Archival EDTA plasma samples (n ϭ 13) were diluted 1:10 in assay buffer and measured in the three TR-FIAs at 4, 23, and 30°C.
We addressed assay tolerance toward pH variations in biological samples by adjusting EDTA plasma, citrate plasma, and uPAR-depleted donor citrate plasma to which we had added 961 pmol/L uPAR(I) or 325 pmol/L uPAR(I-III) to pH 6.5, 7.5, 8.5, or 9.5 with negligible amounts of 10 mol/L HCl or 10 mol/L NaOH. These samples were then diluted 1:10 in assay buffer adjusted to the same pH (with 10 mol/L HCl or 10 mol/L NaOH) as the samples before analysis.
stability of uPAR calibrators and endogenous uPAR in biological samples
We diluted assay calibrators containing 325 pmol/L uPAR(I-III) and 961 pmol/L uPAR(I) in assay buffer and froze them; we subsequently thawed the samples quickly at 37°C and then left them at room temperature for 1 h before refreezing them. The samples passed through one to six such freeze-thaw cycles before they were measured in the three TR-FIAs. Fresh serum and EDTA plasma samples from six donors were subjected to four to seven freeze-thaw cycles (thawed at room temperature and left thawed for 1 h before refreezing) before they were diluted 1:10 in assay buffer and measured by the three TR-FIAs.
Results
validation of the TR-FIAs
Sensitivity. The variation between results obtained for calibrators on different plates demonstrated how reproducible the calibration curves were. The means of 12 calibration curves for each of the three assays, with their respective CVs, are shown in Fig. 3 . TR-FIA 2 was the only assay that reliably measured uPAR over the whole concentration range tested, with a CV Ͻ20% for the lowest calibrator (0.455 pmol/L) and Ͻ15% for the rest (Fig. 3B) . For the other two assays, the CVs were Ͻ15% for all but the lowest calibrators measured, for which the CV in both cases was 21% at 0.455 and 1.35 pmol/L for TR-FIA 1 and TR-FIA 3, respectively (Fig. 3, A and C) .
The detection limit of TR-FIA 1 and TR-FIA 2 was 0.3 pmol/L, whereas it was 1.9 pmol/L for TR-FIA 3. The limit of quantification was determined in uPAR-depleted citrate plasma to which the analytes were added and was Ͻ1. uPAR(I-III) and uPAR(II-III) were tested in TR-FIA 2, the limits of quantification were 1.3 and 1.6 pmol/L, respectively. The least sensitive assay was TR-FIA 3, for which 2.9 pmol/L uPAR(I) was the lower limit of quantification.
Specificity. We tested the specificities of the assays by separately adding equimolar amounts of uPAR(I-III), uPAR(II-III), and uPAR(I) to each of the assays ( Table 2 ). The amounts of uPAR(I-III) and uPAR(I) were measured directly in TR-FIAs 1 and 3, and the amount of uPAR(II-III) was calculated by subtracting the moles of uPAR(I-III) measured in TR-FIA 1 from those of uPAR(I-III) and uPAR(II-III) measured in TR-FIA 2. In accordance with the specificities of the antibodies used in the assays, TR-FIA 1 was selective for uPAR(I-III), TR-FIA 2 for uPAR(I-III) and uPAR(II-III), and TR-FIA 3 for uPAR(I). The only significant cross-reactivity was in TR-FIA 3, which measured 4% of the uPAR(I-III) added, in good agreement with the effect of the peptide AE120 used in this assay to prevent binding of Eu-R3 to uPAR(I-III) (see Fig. 2 ).
To further verify the specificity of the new TR-FIAs, we used them in combination to quantify the cleavage of purified uPAR(I-III) incubated with chymotrypsin in a time-course experiment (Fig. 4A) (Table 1) , the combined concentrations of uPAR(I-III) and uPAR(II-III) remained constant throughout the cleavage reaction as assessed by TR-FIA 2. The cleavage profile detected by the TR-FIAs (Fig. 4A ) was verified by Western blotting (Fig. 4B) . Trypsin cleavage of uPAR(I-III) showed similar results (data not shown).
. The amount of detected uPAR(I) increased concomitantly with a proportional loss of uPAR(I-III). Concordant with the stated equimolar detection of uPAR(I-III) and uPAR(II-III) by R23
The sample with the most extensive chymotrypsin cleavage was then subjected to size-exclusion chromatography on a Superdex 75 column, and the collected fractions were subsequently measured by the TR-FIAs (Fig.  4C) . Different uPAR forms could be identified and quantitatively measured by the TR-FIAs on these fractions. To directly test the effect of AE120 in the TR-FIA 3, we included an assay without the antagonist added. The peaks at the uPAR(I) position that were obtained in this assay and TR-FIA 3 were completely overlapping, whereas omission of AE120 led to a strong increase in the peak at the uPAR(I-III) position (Fig. 4C) . This demonstrated that the presence of AE120 in TR-FIA 3 affects only uPAR(I-III) measurements.
Precision and accuracy. We determined intraassay precision by measuring 12 replicates of the donor citrate plasma pool in the three TR-FIAs and calculating the CVs. In addition, donor citrate plasma to which 480 pmol/L uPAR(I) and 162 pmol/L uPAR(I-III) had been added was assayed, with more than 70 replicates in each assay ( Table  3) . The CVs were Ͻ8% in all cases except for plasma with no added analyte assayed in TR-FIA 3. This is most probably because the amount of uPAR(I) in the measured 1:10-diluted sample was below the limit of quantification. The CV was 4.8% for TR-FIA 3 when we assayed the sample with analyte added (Table 3) .
We determined interassay precision by analyzing the variation in the citrate plasma pool (n ϭ 47) and citrate plasma with added analyte (ϳ20 samples of each). As shown in Table 3 , the mean values were essentially the same as those for the intraassay precision study, and the CVs for the plasmas with added protein were acceptable (Ͻ11%). For plasma with no added protein, the CVs were higher, ϳ15% for TR-FIA 1 and TR-FIA 2 and 30% for TR-FIA 3. The most plausible explanation for the high CV in TR-FIA 3 is the low amount of uPAR(I) in the diluted sample, which was below the limit of quantification.
We assessed the accuracy of the assays by measuring the recoveries of dilution series of purified uPAR forms added to pooled citrate plasma in concentration ranges of 3.9 -769 pmol/L for uPAR(I), 1.9 -381 pmol/L for uPAR(II-III), or 1.3-260 pmol/L for uPAR(I-III). Shown in Table 4 are the recoveries, calculated as the ratios of the linear regression coefficients of the plasma samples with added protein and those of the pure analytes in assay buffer. In all cases the recoveries were between 93% and 105%.
Identical results were obtained when these assays were performed at 4, 23, or 30°C (data not shown). Furthermore, the assays were insensitive to pH variations between 6.5-9.5 during sample incubation (data not shown).
Because unintended cleavage of uPAR(I-III) in vitro during sample processing could cause interference in the ratios determined for the different uPAR forms, we examined the stabilities of the different uPAR forms under various processing conditions. We observed no significant differences in absolute concentration or changes in the ratio of the uPAR forms being measured subsequent to freezing and thawing of fresh serum and EDTA-plasma samples or in purified preparations of uPAR(I-III) and uPAR(I) (data not shown).
Effect of uPA on uPAR measurements. The Mabs R3 and R23 used for detection in the TR-FIAs do not bind uPA/uPAR complexes [Rønne et al. (23 ) and List et al., unpublished results]. Therefore, it would be expected that complexes formed between uPA and uPAR would not be measured in the TR-FIAs. To investigate whether uPA affected the signals obtained in the three TR-FIAs, active-site-mutated uPA (uPA S356A ) was added to a uPAR(I-III) preparation, which subsequently was analyzed by TR-FIA and suPAR ELISA (33 ) . Whereas the addition of uPA only marginally affected the signal in the ELISA, the signals in TR-FIA 1 and TR-FIA 2 were reduced by Ͼ50% when samples containing equimolar concentrations of uPAR and uPA were measured. A threefold molar excess of uPA reduced signals in the two TR-FIAs further, to 35% and 26%, respectively, of the signals obtained when no uPA was added. In TR-FIA 3, no signal was generated in the presence of uPAR/uPA complexes.
endogenous uPAR forms in patient blood and urine
To define the specificities of the assays more rigorously, we subjected donor EDTA-plasma pool to which uPAR(I), uPAR(II-III), or uPAR(I-III) had been added to sizeexclusion chromatography (Fig. 5) . Plasma from the same batch, without added analyte, was included for comparison (Fig. 5A) . The results demonstrated the capability of the TR-FIAs to detect the specific uPAR forms. Added uPAR(I) was thus detected by TR-FIA 3 only and at an elution position that corresponded to its small size (Fig. 5B) . Addition of uPAR(II-III) to samples led to a dramatic increase in the signal at a position consistent with the size of uPAR(II-III) in TR-FIA 2 (Fig. 5C) . Finally, when uPAR(I-III) was added, the signals corresponding Clinical Chemistry 50, No. 11, 2004 to uPAR(I-III) were higher in both assays that measured this protein (Fig. 5D ). The recoveries from the column were 84% (n ϭ 9), 98% (n ϭ 9), and 95% (n ϭ 11) for uPAR(I), uPAR(I-III), and uPAR(II-III), respectively.
To assess the performance of the assays on bonafide patient samples, we analyzed EDTA plasma from a patient with prostate cancer after fractionation by sizeexclusion chromatography (Fig. 6A) . Close examination of the obtained elution profiles revealed that comparable uPAR forms were eluted at identical positions irrespective of their origin (compare Fig. 4C and Fig. 6A ). EDTA plasma from the prostate cancer patient contained detectable amounts of uPAR(I), in contrast to the EDTA-plasma pool from healthy donors (Fig. 5A ). In addition, the concentrations of uPAR measured with TR-FIA 2 were considerably higher in the patient sample than in the donor plasma (Fig. 5A and Fig. 6A) . A sizable fraction of the total uPAR content appeared to be uPAR(II-III); the area under the peak derived from TR-FIA 2 was considerably larger and covered later-eluting fractions than did the peak obtained with TR-FIA 1. Other patient samples, including citrate plasma and serum, yielded comparable profiles (data not shown). In contrast, urine from a patient with acute myeloid leukemia revealed a completely different profile; the prevailing form in this case was uPAR(I). Some uPAR(II-III) was also present, whereas uPAR(I-III) was barely detectable (Fig. 6B) .
Discussion
The immunoassays presented here specifically and quantitatively measure uPAR(I-III), uPAR(I-III) plus uPAR(II-III), and uPAR(I). In TR-FIA 3, which measures uPAR(I), the signal from uPAR(I-III) is blocked by addition of the peptide antagonist AE120 (26 ) . The functional epitope for this peptide antagonist resides mainly in domain III, suggesting that a conformational change is the cause of the AE120-induced inhibition of R3 binding to uPAR(I-III).
Although uPAR(II-III) cannot be measured directly by the present assays, uPAR(II-III) can be quantified by subtracting the measured moles of uPAR(I-III) in TR-FIA 1 from the moles of uPAR measured with TR-FIA 2. However, a result obtained by such a calculation will have a greater CV than a direct measurement, particularly if the amount of uPAR(I-III) is higher than that of uPAR(II-III). To design an assay that directly measures uPAR(II-III) would, however, necessitate the development of a new antibody specific for this form. Ideally, such an antibody should require a conformational change of the linker region after cleavage. There have been reports that such a conformational change does occur in the linker region as a result of proteolytic cleavage by at least matrix metalloproteinase-12 (34 ) . Characterization of this putative neoepitope presumably specific for uPAR(II-III) is, however, further complicated by the fact that the linker region between domains I and II exhibits different conformations depending on the presence of the glycolipid anchor on uPAR (35 ) . To date, it has not been possible to design ELISAs to measure the uPAR forms separately because of changes in the affinities and specificities of Mabs after biotinylation (36 ) . The specificity problem was most evident when plasma samples were measured and was related to the degree of biotinylation of the different uPAR Mabs. In ELISA, more than 100 biotin molecules per molecule of detection Mab are often used. However, the very sensitive detection system in TR-FIA requires only ϳ1 europium molecule per molecule of Mab, and we have not detected any nonspecific reactions with plasma samples when we used Eu 3ϩ -labeled R3 or R23. The TR-FIAs have been validated for measurements of uPAR variants in citrate plasma and were shown to be robust and well suited for analysis of clinical samples. Validation will be needed on any samples before the assays can be used to quantify uPAR forms in serum, urine, ascites, and other human body fluids, tissue and cell extracts, and cell culture media. However, when we subjected urine to size-exclusion chromatography and subsequently measured the different uPAR forms in the eluted fractions, we could identify and quantify the different uPAR forms in this matrix (Fig. 6B) .
Cleaved forms of uPAR have previously been identified in extracts from xenotransplanted tumors by Western blotting (9 ) , in urine from patients with acute myeloid leukemia by immunoprecipitation combined with Western blotting (17 ) , and in cystic fluid from patients with ovarian cancer by immunoaffinity purification and Western blotting (16 ) . However, these methods are neither quantitative nor suited for the high throughput required when analyzing clinical samples for diagnostic or prognostic studies.
Complexes of uPA and uPAR have been detected in blood from breast cancer patients and healthy controls by an ELISA designed for the detection of these complexes (37 ) . In tissue lysates, the concentrations of uPA/uPAR complexes are unknown but may be expected to be significant. However, use of the proposed TR-FIAs to detect the presence of such complexes will influence only the quantification of intact uPAR because uPAR(II-III) cannot bind uPA and liberated domain I will bind uPA poorly, if at all (4, 5 ) . To get an estimate of all forms of uPAR in a sample, one could measure the total amounts of both uPAR(I-III) and uPAR(II-III) with the ELISA described previously (15, 33 ) and use the TR-FIAs described in this study to measure the specific uPAR forms. The amounts measured with the ELISA should equal those measured with TR-FIA 2 if no complexes are present. If all uPAR is in the cleaved form, there will be no signal in TR-FIA 1. If the sample contains a mixture of uPA/uPAR complexes, uPAR(I-III), and uPAR(II-III), then the amount measured by the ELISA will be higher than that measured by TR-FIA 2.
In conclusion, several ELISAs have been developed to quantify uPAR in various patient samples. These assays measure the sum of intact uPAR and most of its degradation products (25, 33, 38 ) . The use of these ELISAs has led to uPAR being identified as a strong prognostic marker in breast, colorectal, and lung cancer (15, 18 -21 ) . Intact uPAR binds pro-uPA and localizes it to the cell surface where its activation is strongly enhanced by the proximity of cell-surface-bound plasminogen (3 ). Active uPA is capable of cleaving cell-bound uPAR, liberating domain I and leaving the cleaved uPAR(II-III) on the cell surface (7 ) . In contrast, uPAR purified from plasma or cell culture medium cannot be cleaved by physiologically relevant concentrations of uPA (35 ) . However, purified glycolipid-anchored uPAR and soluble uPAR can both be cleaved by plasmin (35 ) . The concentrations of the cleaved forms of uPAR might therefore be correlated to the activity of the plasminogen activation system. Thus, it is potentially important to identify and quantify the different uPAR forms separately, both for basic biological studies on the mechanism of cleavage and shedding of uPAR and for clinical studies to investigate the diagnostic and prognostic significance of the different forms of uPAR. The TR-FIAs presented here make such studies possible.
